Journal article
Ceramides in Metabolism: Key Lipotoxic Players
Annual review of physiology, Vol.83(1), pp.303-330
02/10/2021
DOI: 10.1146/annurev-physiol-031620-093815
PMCID: PMC7905841
PMID: 33158378
Abstract
The global prevalence of metabolic diseases such as type 2 diabetes mellitus, steatohepatitis, myocardial infarction, and stroke has increased dramatically over the past two decades. These obesity-fueled disorders result, in part, from the aberrant accumulation of harmful lipid metabolites in tissues not suited for lipid storage (e.g., the liver, vasculature, heart, and pancreatic beta-cells). Among the numerous lipid subtypes that accumulate, sphingolipids such as ceramides are particularly impactful, as they elicit the selective insulin resistance, dyslipidemia, and ultimately cell death that underlie nearly all metabolic disorders. This review summarizes recent findings on the regulatory pathways controlling ceramide production, the molecular mechanisms linking the lipids to these discrete pathogenic events, and exciting attempts to develop therapeutics to reduce ceramide levels to combat metabolic disease.
Details
- Title: Subtitle
- Ceramides in Metabolism: Key Lipotoxic Players
- Creators
- Bhagirath ChaurasiaScott A Summers - University of Utah
- Resource Type
- Journal article
- Publication Details
- Annual review of physiology, Vol.83(1), pp.303-330
- DOI
- 10.1146/annurev-physiol-031620-093815
- PMID
- 33158378
- PMCID
- PMC7905841
- NLM abbreviation
- Annu Rev Physiol
- eISBN
- 9780824303839; 0824303830
- ISSN
- 0066-4278
- eISSN
- 1545-1585
- Grant note
- R01 DK115824 / NIDDK NIH HHS P30 DK020579 / NIDDK NIH HHS R43 DK116450 / NIDDK NIH HHS R44 DK116450 / NIDDK NIH HHS R01 DK124326 / NIDDK NIH HHS R01 DK122001 / NIDDK NIH HHS
- Language
- English
- Date published
- 02/10/2021
- Academic Unit
- Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984359578602771
Metrics
14 Record Views